Orientation and density control of bispecific anti-HER2 antibody on functionalized carbon nanotubes for amplifying effective binding reactivity to cancer cells

Nanoscale
Hye-In KimJong-Ho Kim

Abstract

Nanomaterial bioconjugates have gained unabated interest in the field of sensing, imaging and therapy. As a conjugation process significantly affects the biological functions of proteins, it is crucial to attach them to nanomaterials with control over their orientation and the nanomaterial-to-protein ratio in order to amplify the binding efficiency of nanomaterial bioconjugates to targets. Here, we describe a targeting nanomaterial platform utilizing carbon nanotubes functionalized with a cotinine-modified dextran polymer and a bispecific anti-HER2 × cotinine tandem antibody. This new approach provides an effective control over antibody orientation and density on the surface of carbon nanotubes through site-specific binding between the anti-cotinine domain of the bispecific tandem antibody and the cotinine group of the functionalized carbon nanotubes. The developed synthetic carbon nanotube/bispecific tandem antibody conjugates (denoted as SNAs) show an effective binding affinity against HER2 that is three orders of magnitude higher than that of the carbon nanotubes bearing a randomly conjugated tandem antibody prepared by carbodiimide chemistry. As the density of a tandem antibody on SNAs increases, their effective binding aff...Continue Reading

References

Oct 1, 1996·Biophysical Journal·Y ZhangZ Shao
Jul 27, 2002·Science·Michael J O'ConnellRichard E Smalley
Dec 3, 2002·Science·Sergei M BachiloR Bruce Weisman
Jan 18, 2003·Analytical Biochemistry·Paul PelusoSteffen Nock
Mar 18, 2004·Journal of the American Chemical Society·Chenjie XuBing Xu
Nov 13, 2004·Angewandte Chemie·Eugenii Katz, Itamar Willner
Dec 2, 2004·Journal of the American Chemical Society·Paul CherukuriR Bruce Weisman
Dec 14, 2004·Nature Materials·Paul W BaroneMichael S Strano
Nov 2, 2006·Nature Materials·Igor Medintz
Nov 14, 2006·Angewandte Chemie·Paul W Barone, Michael S Strano
Apr 2, 2008·Proceedings of the National Academy of Sciences of the United States of America·S KerenS S Gambhir
Apr 4, 2008·Nature·Ralph Weissleder, Mikael J Pittet
May 22, 2008·Proceedings of the National Academy of Sciences of the United States of America·Stanley Y ShawRalph Weissleder
Jul 16, 2008·Accounts of Chemical Research·Didier AstrucJaime Ruiz
Aug 15, 2008·Cancer Research·Zhuang LiuHongjie Dai
Sep 2, 2008·Nature Reviews. Drug Discovery·Mark E DavisDong M Shin
Oct 28, 2008·Nature Biotechnology·Zhuo ChenHongjie Dai
Feb 12, 2009·ACS Nano·Jonathan C ClaussenTimothy S Fisher
Sep 8, 2009·Nature Nanotechnology·Yongdong Jin, Xiaohu Gao
Nov 27, 2009·Nature·David A Giljohann, Chad A Mirkin
Mar 11, 2010·Breast Cancer Research and Treatment·S PeterssonC Enerbäck
Mar 24, 2010·Chemical Society Reviews·Sreeman K Mamidyala, M G Finn
May 5, 2010·Clinica Chimica Acta; International Journal of Clinical Chemistry·Sunyoung ParkJunho Chung
Nov 5, 2013·Nature Nanotechnology·Nicole M IversonMichael S Strano

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibody Engineering

Antibody engineering technologies are constantly advancing to improve the clinical effectiveness of monoclonal and bispecific antibodies. Discover the latest research on Antibody Engineering here.